FDA Approves Danicopan With C5 Inhibitor Therapy to Treat EV

Positive phase 3 trial results showed that danicopan was more effective than placebo when treating extravascular hemolysis in paroxysmal nocturnal hemoglobinuria.

Related Keywords

United States , Japan , Bart Scott , Marc Dunoyer , Division Of Hematology , University Of Washington Medical Center , Alexion Pharmaceuticals Inc , Astrazeneca , Add On Therapy , Paroxysmal Nocturnal Hemoglobinuria , Alexion Pharmaceuticals , Washington Medical Center , Clinical Research Division , Fred Hutchinson Cancer Center ,